Shots:

• The P-II SUSTAIN study involves assessing of crizanlizumab 2.5/5 mg/kg vs PBO in 132 SCD patients with sickle cell-related pain crises
• P-II SUSTAIN study results: 2-4 event/yr. (40.5% vs 24.4%); 5-10 event/yr. (28.0% vs 4.2%); with HbSS genotype (31.9% vs 17.0%); with concomitant use of hydroxyurea (33.3% vs 17.5%); median annual rate (63 vs 2.98); no new safety concerns observed
• Crizanlizumab (SEG101) is an anti-P-selectin mAb indicated in prevention of vaso-occlusive crises (VOCs) with SCD- with expected FDA filling in 2019

Click here Ref: Novartis | Image: Sustain Ability